iRhythm Technologies, Inc.

IRTC

IRTC develops and commercializes medical devices for minimally invasive procedures across various specialties.
The company maintains a focus on innovative surgical technologies designed to improve patient outcomes while reducing healthcare costs.

$133.75 -6.43 (-4.59%)

Updated: February 27, 2026, 16:00 EST

Analyzed by Rockflow Bobby Quantitative Model ✓ Updated Daily

Investment Opinion: Should I buy IRTC Today?

Analysis of iRhythm Technologies (IRTC)

Technical Perspective The stock shows clear weakness, having significantly underperformed the market over recent months. While its current price level appears moderately oversold and may find some technical support, the persistent negative momentum suggests continued pressure. Investors should be cautious as the trend has not yet shown convincing signs of reversal.

Fundamental Perspective Fundamentally, the company displays a mixed picture. The return to profitability in the latest quarter and strong gross margins are positive developments. However, the exceptionally high debt load and only modest asset turnover raise concerns about financial sustainability and operational efficiency.

Valuation & Risk Valuation metrics are challenging, with a negative trailing P/E and an extremely high forward P/E, indicating the stock is priced for perfection regarding future growth. Combined with its above-market volatility and substantial debt, these factors present significant risk.

Investment Recommendation Based on the current analysis, IRTC carries substantial risk with an unattractive risk-reward profile. The combination of negative price momentum, high leverage, and demanding valuation makes it difficult to recommend. Investors should wait for clearer signs of sustained fundamental improvement and a more compelling valuation before considering a position.

CTA Banner

IRTC 12-Month Price Forecast

RockFlow Model Forecast: Three Scenarios for 2026

Based on the current outlook, iRhythm Technologies (IRTC) faces a challenging path over the next 12 months. The key positive catalyst is sustaining its recent return to profitability through continued revenue growth and maintenance of its strong gross margins. However, significant risks dominate the narrative, primarily its exceptionally high debt load and a valuation that demands near-perfect execution on future growth expectations. Given the persistent negative momentum, technical weakness, and these substantial fundamental headwinds, the risk-reward profile remains unattractive, suggesting the stock could continue to experience volatility with a bias toward the downside. Without a clear near-term catalyst and considering the demanding valuation, a cautious approach is warranted.

Wall Street Consensus

Most Wall Street analysts are optimistic about iRhythm Technologies, Inc.'s 12-month outlook, with consensus target around $133.75, indicating expected upside potential.

Average Target
$133.75
16 analysts
Implied Upside
+0%
vs. current price
Analyst Count
16
covering this stock
Price Range
$107 - $174
Analyst target range
Buy Buy
15 (94%)
Hold Hold
1 (6%)
Sell Sell
0 (0%)

Bulls vs Bears: IRTC Investment Factors

Overall, IRTC has investment potential but also faces challenges. Here are key factors to weigh before investing.

Bullish Bullish
  • Morgan Stanley price target increase: Stock rose 3.4% after Morgan Stanley raised its price target.
  • Truist Securities maintains Buy rating: Analyst reiterates Buy despite lowering price target to $200.
  • Recent share price pullback opportunity: Valuation reassessment suggests potential buying opportunity at lower price.
Bearish Bearish
  • Multiple insider stock sales: CEO and EVP both sold significant shares, indicating potential concerns.
  • Trade policy uncertainty impact: Stock declined amid new global tariff announcements creating market volatility.
  • Analyst price target reduction: Truist Securities lowered price target from $215 to $200.
Reward Banner

IRTC Technical Analysis

IRTC has demonstrated significant weakness with substantial declines across recent timeframes despite its high-volatility profile.

The stock has experienced sharp deterioration over both one-month (-10.39%) and three-month (-23.48%) periods, significantly underperforming the market by -27.35% over three months. This substantial underperformance indicates broader sector or company-specific pressures rather than general market conditions. The beta of 1.073 confirms the stock's higher volatility relative to the broader market.

Currently trading at $136.07, IRTC sits approximately 36% above its 52-week low but 36% below its 52-week high, placing it in the lower-middle portion of its annual range. The stock appears moderately oversold given the peak-to-current decline of 35.8%, though the persistent negative momentum warrants caution despite current levels suggesting potential technical support.

📊 Beta
1.07
1.07x market volatility
📉 Max Drawdown
-29.3%
Largest decline past year
📈 52-Week Range
$93-$212
Price range past year
💹 Annual Return
+21.4%
Cumulative gain past year
Period IRTC Return S&P 500
1m -11.9% -1.4%
3m -24.8% +4.1%
6m -18.1% +7.5%
1y +21.4% +15.4%
ytd -23.7% +0.4%

IRTC Fundamental Analysis

Revenue & Profitability IRTC demonstrated strong sequential improvement in Q4 2025, with revenue growing 8.3% quarter-over-quarter to $208.9 million. The company returned to profitability with a 4.2% operating margin and 2.7% net margin, a significant improvement from Q3's operating loss. Gross margins remained healthy at 70.9%, indicating solid pricing power despite the operational turnaround.

Financial Health The company maintains excellent liquidity with current and quick ratios above 4.4, supported by a strong cash position of $18.10 per share. However, leverage metrics are concerning with a debt-to-equity ratio of 4.79 and total debt-to-capitalization of 82.7%, indicating heavy reliance on debt financing. The interest coverage ratio of 2.64 suggests adequate but thin coverage of interest obligations.

Operational Efficiency IRTC's operational efficiency improved significantly with ROE reaching 3.7% in Q4 versus negative returns in the prior quarter. Asset turnover remains modest at 0.20, indicating room for improvement in revenue generation relative to the asset base. The 32.6 days sales outstanding reflects reasonable collection efficiency, though the 61.3-day cash conversion cycle suggests working capital management could be optimized.

Quarterly Revenue
$0.2B
2025-12
Revenue YoY Growth
+27.1%
YoY Comparison
Gross Margin
70.9%
Latest Quarter
Free Cash Flow
$-0.2B
Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

RockFlow Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Try Now & Get Tesla Stock Reward

Valuation Analysis: Is IRTC Overvalued?

Valuation Level: IRTC's valuation metrics present conflicting signals. The negative TTM PE ratio indicates lack of current profitability, while the extremely high forward PE of 256 suggests significant investor expectations for future earnings growth. The elevated EV/EBITDA ratio of 387 and negative PEG ratio further confirm the stock appears substantially overvalued based on current financial performance metrics.

Peer Comparison: Without industry average data, precise benchmarking is impossible; however, IRTC's metrics remain concerning even in isolation. A negative trailing PE combined with a forward PE exceeding 250 suggests exceptionally high growth expectations relative to current operations. The negative PEG ratio confirms that even anticipated growth does not justify the current valuation premium.

PE
-83.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -530×-256×
vs. Industry Avg
N/A
Industry PE ~N/A×
EV/EBITDA
386.9x
Enterprise Value Multiple

Investment Risk Disclosure

Volatility Risk: IRTC exhibits moderately elevated volatility risk, with a beta of 1.073 indicating it typically moves slightly more than the broader market. The stock's one-year maximum drawdown of -28.19% further underscores its potential for significant price decline over shorter periods.

Other Risks: The absence of significant short interest reduces the immediate risk of a short squeeze, but it does not eliminate fundamental or sector-specific concerns. Liquidity and other micro-structural risks should be assessed separately based on average trading volume.

FAQs

Is IRTC a good stock to buy?

Neutral, given conflicting signals. The stock is technically oversold after sharp declines and shows improving Q4 profitability with strong liquidity—appealing for contrarian investors. However, elevated debt, concerning valuation metrics (negative TTM PE, high forward PE), and mixed insider/analyst actions create uncertainty. Suitable for risk-tolerant investors with a medium-term horizon who can stomach volatility.

Is IRTC stock overvalued or undervalued?

Based on current metrics, IRTC appears significantly overvalued. Its negative trailing P/E and extremely high forward P/E of 256 suggest current valuation is built entirely on exceptional future growth expectations, which even the negative PEG ratio indicates are not justified. High multiples like the 29.57 P/B and 6.05 P/S ratios further indicate a substantial valuation premium, despite the company only recently returning to minimal profitability and carrying a high debt load. While improved Q4 profitability is a positive, the current price reflects a highly optimistic scenario not supported by near-term fundamentals.

What are the main risks of holding IRTC?

Based on the provided information, here are the key risks of holding IRTC stock, ordered by importance:

1. High Financial Leverage Risk: The company carries a dangerously high debt load, with a debt-to-equity ratio of 4.79 and debt comprising 82.7% of its capital structure, making it vulnerable to rising interest rates or earnings setbacks. 2. Significant Business Momentum and Sector Risk: The stock's severe underperformance (-27.35% over three months) against the market suggests persistent company-specific or sector-wide pressures that are not yet resolved, despite a recent return to profitability. 3. Elevated Volatility and Price Decline Risk: With a beta above 1.0 and a maximum drawdown of -28.19%, the stock is prone to larger price swings and substantial losses than the broader market, as evidenced by recent sharp declines.

What is the price forecast for IRTC in 2026?

Based on the current analysis, here is the IRTC stock forecast for 2026:

Our base case target for IRTC in 2026 is a range of $120-$140, reflecting the challenges of sustaining profitability against a high debt burden. A bull case of $160-$180 would require flawless execution on key growth drivers: continued double-digit revenue expansion and successful debt management to improve its capital structure. The primary assumptions are that the company maintains its recent return to profitability and stabilizes its gross margins near 70%, but the forecast carries high uncertainty given the demanding valuation and sensitivity to any operational missteps. The stock's path will be highly volatile, heavily dependent on quarterly execution against these financial targets.